Pay in 4 interest-free payments of $5.56 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
Common treatments include metformin, myoinositol, and glucagon-like peptide-1 (GLP-1) receptor agonists
Clinical Trials When Semaglutide was injected subcutaneously once a week for 68 weeks, trial participants achieved significant weight loss and other health benefits summarized here: 86% of people achieved at least 5% weight loss, 70% at least 10%, over 50% at least 15%, and one-third at least 20% at 68 weeks 3.7-inch reduction in waist circumference 4.6 decrease in BMI 5 mmHg decrease in systolic blood pressure Lowered fasting blood glucose levels Reduced total cholesterol, VLDL, triglycerides and free fatty acids Lowered C-reactive protein levels (marker of inflammation) Reduced risk of heart attack and stroke Weight loss plateaued at 60 weeks Depicted in the following chart is the observed weight change from the trial: Cardiovascular Benefits In a 3297 type II diabetic patient trial, 83% of participants having cardiovascular disease and/or chronic kidney disease, showed an improvement of kidney function and a decrease in adverse events as follows: 6 Disease Placebo Semaglutide Stroke 2.7% 1.6% Heart attack 3.9% 2.9% CV death 8.9% 6.6% Side Effects and Safety The most common side effects include nausea, vomiting, diarrhea, and constipation
The research team conducted a systematic review of scientific literature published since 2015
In this process, there is a possibility of formation of several impurities which shows impact on yield as well as purity of final API and additional purification techniques required to get pure Semaglutide
